Cartesian Therapeutics (NASDAQ: RNAC), a late clinical-stage biotech focused on cell therapies for autoimmune diseases, granted an employment inducement stock option to one new employee.
The option covers 6,100 shares at an exercise price of $5.86, vests through June 8, 2030, has a ten-year term, and was issued under Nasdaq Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – RNAC
-9.57%1.7x vol
29 alerts
-9.57%Session close to close
+15.1%Peak in 4 hr 52 min
$286.32MMarket Cap
1.7xRel. Volume
In the Jun 15 session, RNAC declined 9.57%, reflecting a notable negative market reaction.
Argus tracked a peak move of +15.1% during that session.
Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
The stock moved -9.6% in the session following this news. A negative reaction despite neutral HR new...
Analysis
The stock moved -9.6% in the session following this news. A negative reaction despite neutral HR news would fit a pattern where financing or capital-structure headlines sometimes met selling, as seen with the non‑dilutive credit facility that preceded a -4.44% move. This announcement details a standard 10‑year option on 6,100 shares at $5.86, so any sharp decline would likely reflect broader positioning and sentiment around the late-stage pipeline rather than the grant itself.
Key Figures
Inducement option shares:6,100 sharesOption exercise price:$5.86Initial vesting fraction:25%+5 more
8 metrics
Inducement option shares6,100 sharesOption grant to one new employee on June 8, 2026
Option exercise price$5.86Closing price on Nasdaq Global Market at grant date
Initial vesting fraction25%Portion vesting on June 8, 2027
Monthly installments36 monthsRemaining vesting after initial 25% cliff
Full vesting dateJune 8, 2030Date when option becomes fully vested
Option term10 yearsMaximum life of the inducement option grant
Nasdaq ruleRule 5635(c)(4)Basis for employment inducement option grant
Pre-news price change8.48%RNAC 24h move ahead of this June 12, 2026 release
Q1 2026 loss with higher R&D for Descartes-08 and detailed pipeline update.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
RNAC has often reacted positively to strategic and corporate updates, with occasional divergences on financing-related news.
Recent Company History
Over recent months, Cartesian has combined strategic, financial, and corporate updates. A Jun 9 licensing deal with WestGene for in vivo CAR‑T in autoimmune disease saw a +18.26% reaction. A May 26 non‑dilutive credit facility of up to $150M led to a -4.44% move. Prior inducement grants on May 1 coincided with a +11.41% gain, while Q1 2026 earnings on Apr 30 and a financing/pipeline update triggered moderate declines. Today’s small inducement award fits this pattern of frequent HR and capital-structure news around a late-stage pipeline.
Key Terms
cell therapy, nasdaq global market, employment inducement incentive award plan, nasdaq listing rules
4 terms
cell therapymedical
"a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases"
Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.
nasdaq global marketfinancial
"the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
employment inducement incentive award planfinancial
"pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan"
An employment inducement incentive award plan is a program that gives new hires upfront or time‑based rewards—often company stock, options or cash—designed to persuade talent to join and stay. Think of it as a signing bonus that vests over time to align the new employee’s interests with the company’s future performance. Investors care because these awards create ongoing costs and can dilute existing ownership, while shaping management incentives and retention.
nasdaq listing rulesregulatory
"granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On June 8, 2026, the Company issued to this employee an option to purchase an aggregate of 6,100 shares of the Company’s common stock with an exercise price of $5.86, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 8, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the option will be fully vested on June 8, 2030. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
What did Cartesian Therapeutics (NASDAQ: RNAC) announce on June 12, 2026?
Cartesian Therapeutics announced an employment inducement stock option grant to a new employee. According to Cartesian Therapeutics, the option covers 6,100 shares of common stock, was granted on June 8, 2026, and is intended as a material inducement to employment under Nasdaq rules.
How many RNAC shares are included in the new inducement stock option and at what exercise price?
The new inducement stock option covers 6,100 shares of Cartesian Therapeutics common stock. According to Cartesian Therapeutics, the option has an exercise price of $5.86, equal to the closing trading price of the company’s stock on the Nasdaq Global Market on the June 8, 2026 grant date.
What is the vesting schedule for Cartesian Therapeutics’ June 8, 2026 inducement option grant (NASDAQ: RNAC)?
The inducement option vests over four years. According to Cartesian Therapeutics, 25% of the option vests on June 8, 2027, with the remaining portion vesting in thirty-six substantially equal monthly installments, so the option becomes fully vested on June 8, 2030.
What is the term of the new RNAC inducement stock option granted by Cartesian Therapeutics?
The new inducement stock option has a ten-year term. According to Cartesian Therapeutics, the option was granted on June 8, 2026, giving the employee the right to purchase 6,100 shares at $5.86 per share any time before the option expires ten years from grant.
Under which plan and Nasdaq rule was Cartesian Therapeutics’ RNAC inducement grant issued?
The inducement grant was issued under Cartesian Therapeutics’ Amended and Restated 2018 Employment Inducement Incentive Award Plan. According to Cartesian Therapeutics, the option was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employee’s entry into employment with the company.
How might the June 2026 RNAC inducement grant affect existing Cartesian Therapeutics shareholders?
The announcement describes a stock option for 6,100 shares to one employee. According to Cartesian Therapeutics, the option is an inducement award; the disclosure does not discuss broader impacts on existing shareholders, dilution levels, or any changes to overall capital structure.
